..., provided the original work is properly cited. Abstract Background Hepatitis C virus (HCV) infection is associated with reduced bone mineral density (BMD) and increased fracture risk. The structural underpinnings for skeletal fragility with HCV and contributions of inflammatory cytokines remain unknown...

... the original work is properly cited. Abstract People who use drugs (PWUD) are increasingly acquiring and transmitting hepatitis C virus (HCV) and being admitted to the hospital for often costly non-HCV related conditions. Traditionally, treatment of HCV has been deferred to the outpatient setting. However...

..., Standard Journals Publication Model ( https://dbpia.nl.go.kr/pages/standard-publication-reuse-rights ) Abstract Background Hepatitis C virus (HCV) is a leading cause of infectious disease death in the United States. Although highly effective direct-acting antiviral (DAA) regimens are well established...

..., Standard Journals Publication Model ( https://dbpia.nl.go.kr/pages/standard-publication-reuse-rights ) Abstract Background Incarcerated people are disproportionately burdened with hepatitis C virus (HCV) infection and experience elevated risk of re-infection following treatment. Medication for opioid...

... of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background Innovative strategies are required to treat hepatitis C (HCV) among...

... RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected]. Abstract Background Global study data show injection drug use is driving upwards of 79% of all new hepatitis C virus (HCV) cases in high-income countries. Low...

... Hepatitis C Monoinfection and Coinfection with HIV in the District of Columbia. A diagram of the outcomes in the original ASCEND trial with retreatment and reassessment outcomes in the subsequent 5 years Of the 36 patients with treatment failure, 26 were re-treated predominantly with Sofosbuvir...

... License ( https://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract People who inject drugs (PWID) account for the majority of hepatitis C virus (HCV) infections in the United...

... : 199212 . 7 Sollima S , Milazzo L , Vassalini P   et al   Recurrence of mixed cryoglobulinaemia vasculitis following influenza vaccination despite clearance of hepatitis C virus infection . Clin Exp Rheumatol   2018 ; 36 ( Suppl 111 ): 161 – 2 . 8 Sollima S , Milazzo L...

... is known about 5-methylcytosine (m⁵C) modification in the genomes of Flaviviruses. Herein, we demonstrate that hepatitis C virus (HCV), dengue virus, and Zika virus contain high levels of viral RNA m⁵C modification. We find that m⁵C modification in HCV RNA genome is located...

... to the submitted work. All other authors report no potential conflicts. 02 12 2024 23 01 2025 11 02 2025 Abstract Background The hospital-led interventions yielding the best hepatitis C virus (HCV) testing and treatment uptake are poorly understood. Methods We searched Medline, Embase...

...; Gallican Rwibasira Abstract Sofosbuvir/velpatasvir/voxilaprevir is recommended for hepatitis C virus (HCV) retreatment in those who fail initial treatment but is unavailable in resource-limited settings. We describe a government sofosbuvir/velpatasvir + ribavirin (SOF/VEL + RBV) × 24 weeks retreatment...

... service participation before a person's first HCV report was dichotomized as “yes” or “no.” History of injection drug use was obtained from HIV transmission risk factor history and dichotomized as “yes” or “no.” Access to hepatitis C treatment in Pennsylvania has increased since the Food and Drug...

... key populations, to achieve HCV microelimination among PWH. Table 1. Prevalence of Hepatitis C Viremia Among People With Human Immunodeficiency Virus in the United States by Direct-Acting Antiviral Era and Demographic Group ^{a , b} Characteristic IFN-Based DAA Era 2011–2013 (n...

... preexposure prophylaxis users. HCV antibody testing was suboptimal, although screening frequency followed the recommended annual schedule. Giving goods/services for sex was more common among those who tested HCV seropositive. cohort analysis hepatitis C virus incidence preexposure prophylaxis...

..., distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background The burden of hepatitis C virus (HCV)–related hospitalizations is substantial, particularly among people with HIV and HCV. In Ontario, Canada, use of direct-acting antivirals (DAAs) increased...

..., or chlamydia between SVR and repeat viremia 5 4.5 Incarceration between end of treatment and repeat viremia 1 0.9 False-positive Clinically determined with confirmatory subsequent negative hepatitis C virus viral load 13 11.8 Presumed late relapse No genotype change or identified risk factors...

... submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Abstract Background Simplified approaches to hepatitis C virus (HCV) treatment delivery are needed to meet elimination goals...

... interests. 04 06 2024 22 11 2024 07 01 2025 Published by Oxford University Press on behalf of National Academy of Sciences 2024. 2024 This work is written by (a) US Government employee(s) and is in the public domain in the US. Abstract Global elimination of chronic hepatitis C (CHC) remains...

...; no compensation was provided for treatment initiation in either group. Abstract Background Hepatitis C virus (HCV) elimination requires treating people who use drugs (PWUD), yet <10% of PWUD in the United States access HCV treatment; access is especially limited in rural communities. Methods We...